Loading
companiesCompany
SWOG Cancer Research Network
aka SWOG, Southwest Oncology Group
SWOG is one of the US National Cancer Institute's cooperative groups: thousands of community and academic sites running practice-changing trials, including the 2026 first-line Hodgkin lymphoma result.
Overview
Founded 1956 (Southwest Oncology Group). NCI National Clinical Trials Network member with >12,000 members at >1,300 sites. Landmark trials include S1826 (nivolumab-AVD in advanced Hodgkin lymphoma, FDA approval March 2026), S1418/BR006 (adjuvant pembrolizumab in TNBC), and the de-escalation trial SCARLET (S2212) in stage II-III TNBC. Statistical centre at Fred Hutchinson Cancer Center.
Headquarters
Portland, OR, US
Scorecard
All companies#94of 1243 companies, score 52
- approved products +6
- targets +2
- modalities +2
- regions +6
- 24-month regulatory events +6
- registry trials +30
1 approved, 0 in phase 3, 0 earlier, 1 targets, 1,322 registry studies. Formula on the scorecards page.
Website
Founded
1956
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to SWOG Cancer Research Network, including child institutions. 42 works · 1,880 citations · 67% open access · 50% clinical trials · 0% reviews.
Oncology works per year
22022
142023
72024
52025
142026
Most works
- Elad Sharon16 works
- Megan Othus15 works
- Sandip Pravin Patel13 works
- Young Kwang Chae13 works
- Charles D. Blanke10 works
- Razelle Kurzrock10 works
- Liam Il‐Young Chung7 works
- Christopher W. Ryan7 works
- Christine M. McLeod7 works
- Howard Streicher7 works
Most cited
Alex F. Herrera
Chief, Division of Lymphoma, City of Hope; SWOG Executive Officer, Leukemia/Lymphoma/Myeloma
Hodgkin lymphomaImmunotherapyCooperative group trials
Led the SWOG S1826 trial that made nivolumab part of first-line Hodgkin lymphoma treatment.
Anne C. Chiang
SWOG Executive Officer, Breast and Lung; Associate Professor, Yale School of Medicine
Lung cancerSmall-cell lung cancerCooperative group trials
Anne Chiang is a thoracic oncologist overseeing SWOG's breast and lung trial portfolios.
Charles D. Blanke
Chief Medical Officer, SWOG Cancer Research Network; Professor, Oregon Health & Science University
Gastrointestinal oncologyGISTClinical trial leadership
Charles Blanke is a GI oncologist who chaired SWOG for a decade and led early imatinib trials in GIST.
Dawn L. Hershman
Group Co-Chair, SWOG Cancer Research Network; Professor of Medicine and Epidemiology, Columbia University
Breast cancerCancer care deliverySurvivorship
Breast oncologist who co-leads SWOG and studies adherence, toxicity, and how care is actually delivered.
Hagen F. Kennecke
SWOG Executive Officer, Gastrointestinal and Melanoma; Professor, Oregon Health & Science University
Gastrointestinal oncologyRectal cancerCooperative group trials
Hagen Kennecke is a GI oncologist who leads SWOG's gastrointestinal and melanoma committees.
Kathy S. Albain
Vice Chair, Clinical Trials Partnerships, SWOG; Professor of Medicine, Loyola University Chicago
Breast cancerLung cancerGenomic assays
Breast and lung oncologist who led the trials showing gene tests can guide chemotherapy decisions.
Mariana Chavez-MacGregor
Professor, Breast Medical Oncology and Health Services Research, MD Anderson; SWOG Executive Officer for International Affairs
Breast cancerHealth services researchCooperative group trials
Mariana Chavez-MacGregor is a breast oncologist who studies how care is delivered and leads SWOG's international work.
Michael LeBlanc
Group Statistician, SWOG Cancer Research Network; Member, Public Health Sciences Division, Fred Hutchinson Cancer Center
BiostatisticsClinical trial design
Michael LeBlanc is the statistician behind SWOG's trials, based at Fred Hutch's statistical centre.
Neeraj Agarwal
SWOG Executive Officer, Genitourinary and Early Therapeutics; Professor of Medicine, Huntsman Cancer Institute, University of Utah
Prostate cancerKidney cancerTargeted therapy
GU oncologist who led TALAPRO-2 and other trials combining PARP inhibitors with hormone therapy.
Primo N. Lara Jr.
Group Co-Chair, SWOG Cancer Research Network; Director, UC Davis Comprehensive Cancer Center
Genitourinary oncologyLung cancerClinical trials
Primo Lara is a GU and lung oncologist who co-chairs SWOG and directs UC Davis's cancer centre.
Priyanka Sharma
Professor of Medicine, University of Kansas Cancer Center; Study Chair, SWOG S2212 (SCARLET)
Triple-negative breast cancerPlatinum chemotherapyDe-escalation trials
Priyanka Sharma is a TNBC trialist testing whether anthracyclines can be dropped from pre-surgery treatment.
Virginia Sun
Professor, Population Sciences and Surgery, City of Hope; SWOG Executive Officer, Palliative Care and Survivorship
SurvivorshipPalliative careSymptom science
Virginia Sun is a nurse scientist who leads SWOG's supportive care and survivorship research.
Notes
top- NCTN cooperative group
- S1826 Hodgkin lymphoma
- SCARLET S2212 (TNBC de-escalation)
- Cancer control and survivorship
rctNew England Journal of Medicine 2024changed practice189 citations
SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults
S1826 moved checkpoint blockade into first-line Hodgkin lymphoma and made N-AVD a preferred regimen for advanced disease in patients from adolescence to older age, while removing radiotherapy for most. It also showed the value of a single trial spanning paediatric and adult groups. Longer follow-up is needed for overall survival and late immune effects in young patients.
observationalJournal of Clinical Oncology 2015changed practice283 citations
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
This single-arm trial is why NCCN lists chemoradiation after a positive margin or involved nodes. The near-identical survival after R0 and R1 resection is suggestive but unproven; no randomised trial has followed, and the UK does not routinely offer it.
Similar pages
not linked directly; found by shared links- CompanyECOG-ACRIN Cancer Research Group
Shares A publicly held library of investigational drugs available for academic combination trials, Follow every trial participant for 30 years through registry linkage, A fixed share of trial-group funding for getting proven care to patients, ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) and the tag cooperative-group.
- CompanyAlliance for Clinical Trials in Oncology
Shares ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials), Lung-MAP (SWOG S1400 and S1900), Older and multimorbid patients are excluded and undertreated, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on and the tag cooperative-group.
- CompanyNRG Oncology
Shares Winship Cancer Institute of Emory University, ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials), Lung-MAP (SWOG S1400 and S1900), Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on and the tag cooperative-group.
- CompanyCanadian Cancer Trials Group (CCTG)
Shares A publicly held library of investigational drugs available for academic combination trials, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on, Trials enrol too few, too slowly and the tag cooperative-group.
- CompanyChildren's Oncology Group (COG)
Shares Follow every trial participant for 30 years through registry linkage, SWOG S1826, SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults, Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on and the tag cooperative-group.
- CompanyUNICANCER
Shares A publicly held library of investigational drugs available for academic combination trials, Trials enrol too few, too slowly, Triple-negative breast cancer (TNBC) and the tag cooperative-group.
- CompanyGerman Hodgkin Study Group
Shares Hodgkin lymphoma, Nivolumab and the tag cooperative-group.
- CompanyGerman Breast Group (GBG)
Shares Hodgkin lymphoma, Triple-negative breast cancer (TNBC) and the tag cooperative-group.
cancers
3drugs
1ApprovedMonoclonal antibody (anti-PD-1)
Nivolumab · Opdivo / Opdivo Qvantig (SC)
institutions
9Fred Hutchinson Cancer CenterHerbert Irving Comprehensive Cancer Center, Columbia UniversityHuntsman Cancer Institute, University of UtahNational Cancer Institute (NIH)OHSU Knight Cancer InstituteThe University of Kansas Cancer CenterUC Davis Comprehensive Cancer CenterUSC Norris Comprehensive Cancer CenterWinship Cancer Institute of Emory University
trials
13ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)DART (SWOG S1609): nivolumab plus ipilimumab in rare tumoursDRAMMATICINT-0116 (Macdonald trial)Lung-MAP (SWOG S1400 and S1900)Lung-MAP S1400I: nivolumab with or without ipilimumabLung-MAP S1800A: ramucirumab plus pembrolizumabSCARLET (SWOG S2212)SWOG S0809SWOG S1418 / NRG BR006SWOG S1505SWOG S1801SWOG S1826
roadmaps
2ideas
5A fixed share of trial-group funding for getting proven care to patientsA permanent neutral non-profit sponsor for multi-company platform trialsA publicly held library of investigational drugs available for academic combination trialsA randomised trial of adjuvant chemoradiation after margin-positive or node-positive gallbladder cancer resectionFollow every trial participant for 30 years through registry linkage
people
12bottlenecks
3key papers
2SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder CarcinomaSWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults